FDMT - 4D Molecular Therapeutics Inc
IEX Last Trade
15.04
-0.210 -1.396%
Share volume: 418,309
Last Updated: Fri 30 Aug 2024 09:59:55 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$15.25
-0.21
-1.38%
View ratios
| Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
|---|---|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
| Report Date | 2022-08-11 | 2022-11-08 | 2023-03-15 | 2023-05-11 | 2023-08-09 | 2023-11-09 | 2024-02-29 | 2024-05-09 | |
| Assets | |||||||||
| Total Assets | 302.936 M | 280.164 M | 261.846 M | 244.021 M | 352.503 M | 361.613 M | 339.891 M | 629.884 M | |
| Current Assets | 246.523 M | 232.478 M | 220.511 M | 207.040 M | 317.776 M | 328.243 M | 296.588 M | 535.589 M | |
| Inventories | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Other Current Assets | 5.435 M | 4.763 M | 6.957 M | 6.586 M | 7.433 M | 8.579 M | 8.356 M | 9.678 M | |
| Short Term Investments | 5.435 M | 4.763 M | 6.957 M | 6.586 M | 7.433 M | 8.579 M | 8.356 M | 9.678 M | |
| Total Receivables | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Current Cash | 241.088 M | 227.715 M | 213.554 M | 200.454 M | 310.343 M | 319.664 M | 288.232 M | 525.911 M | |
| Total Non-current Assets | 56.413 M | 47.686 M | 41.335 M | 36.981 M | 34.727 M | 33.370 M | 43.303 M | 94.295 M | |
| Property Plant Equipment | 21.097 M | 22.052 M | 22.262 M | 21.614 M | 21.295 M | 20.738 M | 20.126 M | 19.464 M | |
| Other Assets | 14.784 M | 14.512 M | 14.165 M | 13.962 M | 13.432 M | 12.632 M | 12.223 M | 11.889 M | |
| Intangible Assets | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Goodwill | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Liabilities and shareholders’ equity | |||||||||
| Total Liabilities and shareholders’ equity | 302.936 M | 280.164 M | 261.846 M | 244.021 M | 352.503 M | 361.613 M | 339.891 M | 629.884 M | |
| Total liabilities | 30.419 M | 28.720 M | 30.509 M | 25.415 M | 27.359 M | 31.679 M | 32.062 M | 29.323 M | |
| Total current liabilities | 14.331 M | 13.564 M | 15.731 M | 11.278 M | 13.749 M | 18.163 M | 18.951 M | 16.403 M | |
| Accounts Payable | 3.316 M | 1.480 M | 3.322 M | 2.408 M | 3.493 M | 4.713 M | 3.515 M | 4.217 M | |
| Other liabilities | 1.686 M | 1.237 M | 1.309 M | 1.132 M | 1.083 M | 1.485 M | 1.589 M | 1.922 M | |
| Current long term debt | 2.596 M | 2.633 M | 2.655 M | 2.678 M | 3.103 M | 3.126 M | 3.149 M | 3.173 M | |
| Long term debt | 14.402 M | 13.919 M | 13.469 M | 13.005 M | 12.527 M | 12.031 M | 11.522 M | 10.998 M | |
| Other liabilities | 1.686 M | 1.237 M | 1.309 M | 1.132 M | 1.083 M | 1.485 M | 1.589 M | 1.922 M | |
| Minority interest | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Total Shareholder equity | 272.517 M | 251.444 M | 231.337 M | 218.606 M | 325.144 M | 329.934 M | 307.829 M | 600.561 M | |
| Common stock | 32.324 M | 32.386 M | 32.462 M | 32.724 M | 38.335 M | 42.257 M | 43.205 M | 49.272 M | |
| Retained earnings | -261.420 M | -287.111 M | -314.490 M | -343.172 M | -372.788 M | -383.044 M | -415.327 M | -447.728 M |